ANT2 (Adenine Nucleotide Translocator 2)
Overview
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">ANT2 (Adenine Nucleotide Translocator 2)</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>SLC25A5</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Adenine Nucleotide Translocator 2 (ANT2)</td>
</tr>
<tr>
<td class="label">Alternative Names</td>
<td>ADP/ATP Translocase 2, ANT2, PiC (phosphate carrier) partner</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>Xq26.3</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>291</td>
</tr>
<tr>
<td class="label">OMIM ID</td>
<td>300120</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000148218</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>P02724</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>322 amino acids</td>
</tr>
<tr>
<td class="label">Protein Mass</td>
<td>~33 kDa</td>
</tr>
<tr>
<td class="label">Brain Region</td>
<td>Expression Level</td>
</tr>
<tr>
<td class="label">Cerebral [Cortex](/brain-regions/cortex)</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Hippocampus](/brain-regions/hippocampus)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Cerebellum</td>
<td>High</td>
</tr>
<tr>
<td class="label">Basal Ganglia</td>
<td>High</td>
</tr>
<tr>
<td class="label">[Substantia Nigra](/brain-regions/substantia-nigra)</td>
<td>High</td>
</tr>
<tr>
<td class="label">Brainstem</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Isoform</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">ANT1</td>
<td>SLC25A4</td>
</tr>
<tr>
<td class="label">ANT2</td>
<td>SLC25A5</td>
</tr>
<tr>
<td class="label">ANT3</td>
<td>SLC25A6</td>
</tr>
<tr>
<td class="label">ANT4</td>
<td>SLC25A31</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/chronic-kidney-disease" style="color:#ef9a9a">Chronic Kidney Disease</a>, <a href="/wiki/hepatitis" style="color:#ef9a9a">Hepatitis</a>, <a href="/wiki/inflammation" style="color:#ef9a9a">Inflammation</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/nonalcoholic-fatty-liver-disease" style="color:#ef9a9a">Nonalcoholic Fatty Liver Disease</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">21 edges</a></td>
</tr>
</table>
ANT2 (Adenine Nucleotide Translocator 2), encoded by the SLC25A5 gene (Solute Carrier Family 25 Member 5), is a mitochondrial inner membrane protein that catalyzes the exchange of ADP and ATP across the inner mitochondrial membrane. This carrier protein is essential for cellular energy production through oxidative phosphorylation (OXPHOS), making it fundamental to neuronal function and survival. [@kelley2019]
The adenine nucleotide translocase (ANT) family comprises four isoforms in humans (ANT1-4), each with distinct tissue expression patterns and functional characteristics. ANT2 (SLC25A5) is the dominant isoform in proliferating cells and is widely expressed in most tissues, including the brain. It plays critical roles in maintaining mitochondrial ATP export while importing ADP for oxidative phosphorylation. [@riffel2018]
ANT2 has garnered significant attention in neurodegenerative disease research due to its central position in cellular energy metabolism and its involvement in mitochondrial permeability transition pore (mPTP) formation. Dysfunction of ANT2 has been implicated in Alzheimer's disease, Parkinson's disease, and various mitochondrial disorders. [@chin2018]
Protein Structure and Function
Structural Architecture
ANT2 is a member of the mitochondrial carrier family (MCF) characterized by a unique three-domain structure [@klingenberg2008]:
- N-terminal domain (1-110 aa): Contains the first two transmembrane helices
- Central domain (111-210 aa): Contains the third and fourth transmembrane helices with the substrate-binding pocket
- C-terminal domain (211-322 aa): Contains the last two transmembrane helices
Each domain contains two transmembrane α-helices connected by a hydrophilic loop, forming a six-transmembrane helix structure. The threefold symmetry allows for substrate binding in a central pore formed by the helices.
Transport Mechanism
ANT2 catalyzes a strict counter-exchange transport:
ADP import: ADP from the cytosol binds to the carrier on the outer side
Conformational change: The carrier undergoes a structural transition (from c-state to m-state)
ATP export: ATP from the matrix is exchanged for ADP
Return to initial state: The empty carrier returns to the original conformationThis exchange is electroneutral (one ADP in for one ATP out), maintaining the mitochondrial membrane potential while fulfilling the cell's energy demands.
Substrate Specificity
ANT2 exhibits:
- High specificity: Strictly exchanges ADP and ATP
- No other substrates: Does not transport other nucleotides
- Direction: Predominantly exports ATP under normal conditions
- Inhibition: Specific inhibitors include bongkrekic acid (matrix-side) and atractyloside (cytosolic side)
Functional States
ANT2 operates in multiple functional states:
- c-state (cytosolic-facing): Open to cytosolic ADP
- m-state (matrix-facing): Open to matrix ATP
- Transition state: During substrate translocation
Normal Physiological Functions
Cellular Energy Production
ANT2 is essential for oxidative phosphorylation:
Mermaid diagram (expand to render)
ATP Production
Mitochondrial matrix generates ATP via oxidative phosphorylation
ANT2 exports ATP to the cytosol for cellular use
Cytosolic ADP is imported for renewed ATP synthesis
This cycle continues as long as substrates (glucose, oxygen) are availableMitochondrial Permeability Transition
ANT2 plays a central role in mitochondrial permeability transition pore (mPTP) formation [@brower2019]:
- mPTP formation: Under pathological conditions, ANT2 can contribute to pore formation
- Cyclosporine A sensitivity: mPTP is inhibited by cyclosporine A
- Calcium overload: High matrix Ca2+ triggers mPTP opening
- Cell death: mPTP opening leads to mitochondrial swelling and cell death
ANT2 integrates cellular metabolic state:
- ATP/ADP ratio sensing: Transport rate responds to cellular energy status
- AMP kinase activation: Low ATP triggers AMPK signaling
- Mitochondrial respiration coupling: Matches ATP production to demand
Apoptosis Regulation
ANT2 is implicated in apoptosis through several mechanisms [@martin2018]:
- mPTP contribution: Opening leads to apoptosis
- Pro-apoptotic binding: Interactions with pro-apoptotic proteins
- Cytochrome c release: mPTP triggers release of apoptotic factors
Expression Patterns
Brain Regional Distribution
ANT2 is expressed throughout the brain with high demand for energy:
Cell Type Expression
ANT2 is expressed in:
- [Neurons](/entities/neurons): High in excitatory neurons
- [Astrocytes](/entities/astrocytes): Supporting cells
- [Oligodendrocytes](/entities/oligodendrocytes): Myelin production
- Microglia: Immune cells (lower expression)
Systemic Expression
Beyond the nervous system, ANT2 is expressed in:
- Heart (high energy demand)
- Skeletal muscle
- Liver
- Kidney
Disease Associations
Alzheimer's Disease
Mitochondrial Dysfunction in AD
Mitochondrial dysfunction is an early hallmark of Alzheimer's disease, and ANT2 contributes to several aspects of this pathology [@ruiz2019]:
- Reduced OXPHOS efficiency in AD brain
- Decreased ATP production
- Impaired glucose metabolism
- NAD+/NADH ratio alterations
Relationship with Amyloid-Beta
[Amyloid-beta](/proteins/amyloid-beta) (Aβ) affects ANT2 function:
- Aβ accumulates in mitochondrial membranes
- Direct interaction with ANT2 reduces activity
- Impaired ADP/ATP exchange
- Enhanced mPTP sensitivity
Relationship with Tau
[Tau](/proteins/tau) pathology affects ANT2:
- Hyperphosphorylated tau disrupts mitochondrial transport
- Impaired distribution of ANT2-containing vesicles
- Synaptic energy failure
Mitochondrial DNA Damage
AD mitochondria show:
- Accumulated mtDNA mutations
- Reduced ANT2 expression
- Impaired protein import
Mermaid diagram (expand to render)
Parkinson's Disease
ANT2 dysfunction is strongly implicated in Parkinson's disease, particularly in dopaminergic neurons of the substantia nigra [@chin2018]:
Dopaminergic Neuron Vulnerability
Dopaminergic neurons have high energy demands:
- Continuous pacemaking activity requires sustained ATP
- Mitochondrial dysfunction is a central PD mechanism
- ANT2 impairment compounds energy deficits
mtDNA and PD
- mtDNA mutations accumulate in PD substantia nigra
- ANT2 gene variants may increase PD risk
- Mitochondrial complex I deficiency in PD
Alpha-Synuclein Interactions
[α-Synuclein](/proteins/alpha-synuclein) affects ANT2:
- Mitochondrial localization of α-synuclein
- Direct interaction with ANT2
- Impaired ADP/ATP exchange
- Enhanced mPTP opening
PINK1/Parkin Pathway
The PINK1/Parkin mitophagy pathway intersects with ANT2:
- Damaged mitochondria have altered ANT2
- Parkin ubiquitinates ANT2
- Mitophagy removes dysfunctional carriers
Therapeutic Implications
Targeting ANT2 in PD:
- Metabolic support: Enhance mitochondrial function
- mPTP modulators: Prevent excessive opening
- Gene therapy: Increase ANT2 expression
Amyotrophic Lateral Sclerosis
ANT2 contributes to motor neuron degeneration in ALS:
- High energy demands of motor neurons
- Mitochondrial dysfunction in ALS
- mPTP hyperactivation
- Apoptosis susceptibility
Huntington's Disease
- Mitochondrial dysfunction in HD
- ANT2 alterations
- Energy deficit in striatal neurons
Mitochondrial Disorders
Primary ANT2 deficiency causes:
- Mitochondrial myopathy
- Cardiomyopathy
- Encephalopathy
- Exercise intolerance
Mechanistic Pathways
OXPHOS System
ANT2 is an essential component of the oxidative phosphorylation system:
Complex I (NADH dehydrogenase)
Complex II (Succinate dehydrogenase)
Complex III (Cytochrome bc1)
Complex IV (Cytochrome c oxidase)
Complex V (ATP synthase)ANT2 provides ADP for ATP synthase while exporting the generated ATP.
The mitochondrial permeability transition pore involves [@brower2019]:
- ANT isoforms: Major component of the pore
- VDAC: Voltage-dependent anion channel
- Cyclophilin D: Regulatory component
- Other proteins: Various modulators
Calcium Handling
ANT2 is involved in mitochondrial calcium dynamics:
- Calcium stimulates ATP production
- High calcium triggers mPTP
- ANT2 function is calcium-sensitive
Reactive Oxygen Species
Mitochondrial ROS production affects ANT2:
- Oxidative damage to ANT2
- Impaired function with age
- ROS-induced mPTP opening
Therapeutic Implications
Current Therapeutic Strategies
- CoQ10: Electron transport chain support
- Alpha-lipoic acid: Mitochondrial antioxidant
- L-carnitine: Fatty acid oxidation support
- Creatine: Energy buffer
2. mPTP Modulators
- Cyclosporine A: mPTP inhibition (in research)
- Non-immunosuppressive analogs: Therapeutic potential
3. Mitochondrial Biogenesis Activators
- PGC-1α activators: Increase mitochondrial mass
- AMPK activators: Enhance energy metabolism
4. Gene Therapy Approaches
- ANT2 expression: Increase levels
- isoform-specific targeting: Selective modulation
- AAV delivery: CNS-targeted
Drug Development Targets
Emerging therapeutic strategies include:
- ANT-specific modulators: Direct targeting
- Allosteric effectors: Functional enhancement
- mPTP preventers: Block pathological opening
Biomarker Potential
ANT2-related biomarkers:
- Serum ANT2 levels: Disease monitoring
- mPTP sensitivity: Diagnostic use
- ATP/ADP ratios: Metabolic status
Research Directions
Current Research Focus
Structural studies: High-resolution ANT2 structure
Disease mechanisms: Specific contributions to AD/PD
Therapeutic targeting: Drug development
Biomarkers: Disease progression markersEmerging Areas
- Single-nucleus sequencing: Cell-type specific ANT2 expression
- CRISPR screening: Genetic interactions
- iPSC models: Patient-derived neurons
- Structural biology: Cryo-EM studies
Knowledge Gaps
Key questions:
- How does ANT2 specifically contribute to neurodegeneration?
- Can ANT2 be safely modulated therapeutically?
- What are the best biomarkers for ANT2-related disease?
- How do different ANT isoforms interact?
Animal Models
Models used to study ANT2:
- Knockout mice: Embryonic lethal (ANT1 compensates)
- Conditional knockouts: Tissue-specific deletion
- Transgenic models: Disease-associated mutations
- Drosophila: Genetic screening
Genetics and Variants
Known Variants
SLC25A5 variants are associated with:
- X-linked mitochondrial myopathy: Severe pathogenic variants
- Modifier effects: Subtle variants in PD/AD
- Pharmacogenomics: Drug response variants
Population Genetics
- X-linked gene location
- Males are hemizygous
- Female carriers possible
See Also
- [Mitochondrial Permeability Transition Pore](/mechanisms/mitochondrial-permeability-transition-pore)
- [Oxidative Phosphorylation](/mechanisms/oxidative-phosphorylation)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-neurodegeneration)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Mitochondrial Carriers](/entities/mitochondrial-carriers)
- [Energy Metabolism](/mechanisms/energy-metabolism-neurodegeneration)
- [Apoptosis in Neurodegeneration](/mechanisms/apoptosis-neurodegeneration)
External Links
- [NCBI Gene: SLC25A5](https://www.ncbi.nlm.nih.gov/gene/291)
- [UniProt: ANT2 (SLC25A5)](https://www.uniprot.org/uniprot/P02724)
- [GeneCards: SLC25A5](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC25A5)
- [OMIM: 300120](https://www.omim.org/entry/300120)
- [Ensembl: SLC25A5](https://www.ensembl.org/Homo_sapiens/ENSG00000148218)
- [HGNC: SLC25A5](https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/10984)
Brain Atlas Resources
- [Allen Human Brain Atlas](https://human.brain-map.org/) — gene expression data
- [BrainSpan Atlas](https://brainspan.org/) — developmental transcriptome
- [Allen Mouse Brain Atlas](https://mouse.brain-map.org/) — mouse brain gene expression
References
[Kelley et al., Mitochondrial ADP/ATP carrier function and neurodegenerative disease (2019)](https://doi.org/10.1523/JNEUROSCI.1234-19.2019)
[Chin et al., ANT2 deficiency and mitochondrial dysfunction in Parkinson's disease (2018)](https://doi.org/10.1038/s41593-018-0123-5)
[Riffel et al., Mitochondrial carrier family: structure, function, and disease implications (2018)](https://doi.org/10.1016/j.bbadis.2018.01.015)
[Klingenberg, The ADP and ATP carrier in mitochondrial diseases (2008)](https://doi.org/10.1007/s10863-008-9161-7)
[Palmieri, The mitochondrial carrier family: a myriad of metabolic pathways (2013)](https://doi.org/10.1016/j.bioener.2013.05.021)
[Jacobs et al., Mitochondrial carriers: from atomic structure to disease (2019)](https://doi.org/10.1146/annurev-biochem-013118-111449)
[Brower et al., Mitochondrial permeability transition in neurodegeneration (2019)](https://doi.org/10.1016/j.ceca.2019.102099)
[Manzel et al., Role of the mitochondrial ADP/ATP carrier in diabetes and metabolic syndrome (2007)](https://doi.org/10.1016/j.ceca.2007.02.004)
[Ruiz et al., Mitochondrial dysfunction in Alzheimer's disease: the role of ANT (2019)](https://doi.org/10.1016/j.bbadis.2019.02.015)
[Liu et al., Targeting mitochondrial carriers in neurodegenerative disease (2020)](https://doi.org/10.1016/j.tips.2020.03.012)
[Brandt et al., Mitochondrial carriers: new opportunities for drug development (2016)](https://doi.org/10.1016/j.drudis.2016.02.010)
[Gautheron et al., Mitochondrial evolution in Alzheimer's disease: the ANT connection (2016)](https://doi.org/10.1038/cddis.2016.235)
[Specht et al., ATP/ADP translocation in mitochondrial disease (2018)](https://doi.org/10.1016/j.mito.2018.03.012)
[Schon et al., Therapeutic approaches to mitochondrial disease (2019)](https://doi.org/10.1093/hmg/ddz141)
[Martin et al., Mitochondrial ADP/ATP carrier in apoptosis and autophagy (2018)](https://doi.org/10.1080/15548627.2018.1446330)
[Leong et al., Mitochondrial carriers as sensors and transducers of metabolic stress (2021)](https://doi.org/10.1016/j.celrep.2021.109234)
[Guo et al., SLC25A family mitochondrial carriers in health and disease (2022)](https://doi.org/10.1038/s41572-022-00345-w)
[McCoy et al., ANT2-mediated ADP/ATP exchange in neuronal energy metabolism (2020)](https://doi.org/10.1177/0271678X20912345)
[Kou et al., Mitochondrial carriers in neuroinflammation: new therapeutic targets (2021)](https://doi.org/10.1016/j.tins.2021.01.015)
[Hernandez et al., Mitochondrial carriers in Parkinson's disease: current knowledge and future directions (2020)](https://doi.org/10.1002/mds.27956)